Changeflow GovPing Healthcare & Life Sciences Siren Biotechnology ITM Trademark for Gene Therapy
Routine Notice Added Final

Siren Biotechnology ITM Trademark for Gene Therapy

Favicon for changeflow.com USPTO Trademarks - Pharmaceuticals (Class 005)
Published
Detected
Email

Summary

USPTO published Siren Biotechnology's intent-to-use trademark application for the stylized mark 'SIREN BIOTECHNOLOGY' covering pharmaceutical preparations for gene therapy for cancer treatment and related research and development services. The application (TM99737013) was filed on March 31, 2026, with an Intent-to-Use filing basis indicating the applicant has not yet used the mark in commerce but intends to do so.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

Siren Biotechnology filed an Intent-to-Use trademark application with USPTO for its stylized company name covering Class 5 pharmaceutical preparations for gene therapy targeting cancer treatment, as well as research and development services in the pharmaceutical and biotechnology fields. The application (TM99737013) was filed on March 31, 2026.

Trademark applicants and competitors in the gene therapy and oncology pharmaceutical space should review the application to identify potential conflicts with existing marks. No immediate compliance actions are required from most regulated entities. This filing does not create new regulatory obligations but serves as public notice of Siren Biotechnology's intent to use this mark.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Trademark Applications

THE MARK CONSISTS OF OUR COMPANY NAME ‘SIREN BIOTECHNOLOGY’ WITH A STYLIZED DESIGN ELEMENT IN THE LETTER "E" OF SIREN, AND A STYLIZED FONT

Intent to Use TM99737013 Kind: intenttouse Apr 01, 2026

Abstract

Pharmaceutical preparations for gene therapy for the treatment of cancer; Research and development in the pharmaceutical and biotechnology fields

Filing Date

2026-03-31

View original document →

Named provisions

Class 5 - Pharmaceutical preparations for gene therapy Research and development services

Get daily alerts for USPTO Trademarks - Pharmaceuticals (Class 005)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
TM99737013

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Biotechnology companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Trademark Registration
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Trademarks - Pharmaceuticals (Class 005) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!